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Coccidioidomycosis is an infection caused by a dimorphic
fungus endemic to the desert southwest. Coccidioides immitis
and C. posadasii are transmitted by aerosolization of highly
infectious and environmentally resistant spores that are
inhaled when the soil is disrupted. Primary infection is often
manifest as an acute respiratory illness, although the spec-
trumof disease ranges from asymptomatic exposure to severe
and life-threatening disseminated disease.1
History
The ﬁrst case of coccidioidomycosis was described in 1892
involving an Argentinean soldier with skin lesions.2 In 1896,
the ﬁrst case within the United States was reported in a
manual laborer from the San Joaquin Valley, California, with
similar skin lesions.3 This prompted further investigation into
the microbiologic and infectious potential of the organism
and resulted in the inadvertent infection of a Stanford Uni-
versity medical student in 1929. Following the development
of erythema nodosum and his ultimate survival, investigators
surmised his illness was similar to “San Joaquin fever,”
“Desert fever,” or “Valley fever,” a common disorder through-
out central California. Further investigations led by the Kern
County Health Department found most patients reported
signiﬁcant dust exposure, had positive coccidioidal skin test
results, and for the ﬁrst time identiﬁed racial differences in
the risk of dissemination following primary infection.4
Ecology
Coccidioidomycosis is caused by two distinct species,
C. immitis and C. posadasii. Initially it was thought
that C. immitis isolates existed only in California, whereas
C. posadasii accounted for a broader range of endemicity.
However, more recent studies demonstrate considerable
overlap in the geographic distribution of both species. Clini-
cally, they are identical in their presentation and
management.5
Coccidioides spp. are dimorphic fungi endemic to arid,
desert regions. In the soil, they growas amoldwith branching
septate hyphae. During periods of drought or low precipita-
tion, in the late summer and early fall, the hyphae develop
into arthrospores. During these drier periods, the arthro-
spores disarticulate into individual arthroconidia (spores)
that become airborne and are dispersed when the soil is
disturbed (►Fig. 1).6
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Abstract Coccidioidomycosis manifests as a variety of clinical manifestations and ranges in
severity from asymptomatic exposure with resultant immunity to reinfection, to
fulminant, and life-threatening disseminated disease. Primary coccidioidal pneumonia
represents the most common clinical form of infection, and the incidence continues to
increase.Within the endemic region, primary pulmonary coccidioidomycosis represents
up to 29% of all community-acquired pneumonia emphasizing the frequency with which
clinicians encounter this endemic mycosis. Chronic infection develops in 3 to 5% of
patients, and almost all morbidity and mortality observed in coccidioidomycosis occur
in these forms (e.g., chronic pulmonary disease, extrapulmonary manifestations). This
review summarizes the ecology, epidemiology, manifestations of disease, and treat-
ment options currently available for coccidioidomycosis.
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Ecological research has focused primarily on the sapro-
phytic soil phase and the wind, precipitation, and tempera-
ture conditions favoring Coccidioides growth. Most isolates
have been recovered from alkaline, sandy soil, 10 to 30 cm
beneath the surface.7 However, some studies have docu-
mented that Coccidioides is more easily isolated from two
genera of small mammals, pocket mice (Perognathus spp.)
and kangaroo rats (Dipodomys spp.),8 than it is from soil.9,10
Questions remain as to whether Coccidioides requires an
animal “vector” or if it is simply found in disproportionate
quantities in the soil surrounding rodent burrows.11
Epidemiology
Coccidioidomycosis is found only in theWestern hemisphere.
Parts of Arizona, southern New Mexico, western Texas, and
the central valley of California are known to be endemic12–15
(►Fig. 2). Some regions within California and Arizona are
considered “hyperendemic” including Bakersﬁeld, CA, and
both Phoenix and Tucson, AZ. Outside of the United States,
there are reports of coccidioidal infections acquired in parts of
Mexico as well as Central and South America,13,16 although
estimates for the burden of disease within these countries are
not yet available. Beyond the Western hemisphere, sporadic
cases have been reported in other countries; however, evi-
dence suggests the majority of these were acquired via
fomites originating from known endemic regions, or were
misdiagnoses.
A recent report illustrates the signiﬁcant burden of coccid-
ioidomycosis outside of the traditional endemic region.17 In
fact, approximately 10% of cases were diagnosed or treated in
states other than those described above, reiterating the
“global playground” of our patients and the need for infec-
tious disease practitioners in all regions of the United States
to possess a working understanding of the diagnostic and
treatment practices needed during the care of endemic
mycoses.
Recent evidence has identiﬁed three cases of locally
acquired coccidioidomycosis in southeastern Washington.18
Soil sampling obtained from this area has also isolated viable
C. immitis19 conﬁrming endemicity within this location. One
of the environmental isolates is genomically identical to a
clinical isolate from an affected patient, thus conﬁrming
locally acquired infection. This suggests the geographic range
of Coccidioides spp. may be wider than previously recognized
or potentially expanding due to variability and changes in
weather patterns. Ongoing work will hopefully further eluci-
date the range of these fungi.
Consistent with the broadening range of Coccidioides and
the population explosion within the known endemic region,
the incidence of coccidioidomycosis continues to increase.20
Construction and development of previously uninhabited
areas and an inﬂux of nonimmune individuals play a major
role in this increasing trend. There is also a growing popula-
tion of immunosuppressed patients who are more suscepti-
ble to disease with the availability of biologic agents.
Fig. 1 Life cycle of Coccidioides spp.
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Concurrent with the increasing number of cases is a growing
ﬁnancial burden in endemic areas. Hospitalizations due to
coccidioidal infection were estimated to cost more than $2
billion between 2000 and 2011.21
Occupations with heavy exposure to the soil are known to
be at an increased risk for coccidioidomycosis. Construction
workers, agricultural laborers, archaeologists, and excavators
are thosemost frequently exposed to sporeswhile working in
endemic areas.22–24
Patients with conditions causing suppression or altered
function of T-cells are at particular risk for symptomatic and/
or severe disease. This includes patients on immune-modu-
lating medications,25 solid organ and bone marrow trans-
plant recipients,26,27 and human immunodeﬁciency virus
(HIV).28 Other groups at risk include patients in the third
trimester of pregnancy owing to the relative suppression of
cell-mediated immunity during this time period, and the
presence of a cytosolic estrogen receptor within Coccidioides
spp.29
Ethnic predisposition for severe infection has long been
recognized. Although there is no racial predilection for pri-
mary infection, higher rates of dissemination are well known
in Filipinos and African Americans. The risk of dissemination
is estimated to be 10 to 175 times higher in these racial
groups, although the immunological mechanisms for this risk
remain incompletely deﬁned.29 It was thought that the lower
serum vitamin D levels found in darker skinned individuals
may play a role in the acquisition or rate of coccidioidal
dissemination given the essential role of vitamin D in both
innate and acquired immunity; however, contradictory evi-
dence has since been presented.30
Pathophysiology
Coccidioidomycosis is primarily transmitted via respiratory
inhalation of airborne arthroconidia. Once inhaled, the ar-
throconidia are deposited into terminal bronchioles and
enlarge to form spherules. Spherules are then ﬁlled with
thousands of endospores. The spherules later rupture releas-
ing new endospores (►Fig. 3) and propagating the fungal life
cycle in vivo. Dissemination occurs through passage within
lymphatics to extrapulmonary sites, or hematogenous spread
to the bone, brain, skin, etc. Occasionally, coccidioidal infec-
tions can occur from direct inoculation following penetrating
trauma causing localized, cutaneous, and soft tissue
infections.
All people traveling or residing to endemic regions are at
risk for infection given the highly infective nature of arthro-
conidia (ID50 as low as 1 in animal experiments). Although
inhalation of a single spore may be enough to cause illness,
higher spore burdens are more likely to result in signiﬁcant
disease and may precipitate acute respiratory distress syn-
drome (ARDS) with heavy exposure.
Clinical Manifestations
It is important to recognize the disparate and tremendous
interpatient variability in the clinical course of
Fig. 2 Areas endemic for coccidioidomycosis.
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coccidioidomycosis. Although up to 60% of those infected
recall no symptoms and are identiﬁed by positive skin testing
during epidemiologic surveys, 40% of those exposed have
symptoms ranging from a mild and self-limited illness to
pneumonia with severe and life-threatening complications
including disseminated infection.
The predominant symptoms of primary coccidioidal pneu-
monia include cough, fever, and pleuritic chest pain. Differentia-
tion from community-acquired pneumonia in primary infection
can be difﬁcult without additional testing and the diagnosis is
often not initially considered even in endemic areas.31
However, within the endemic region primary coccidioidal
pneumonia accounts for 17 to 29% of all cases of community-
acquired pneumonia32,33 and some have suggested routine
coccidioidal testing for all patients with pulmonary symp-
toms within these regions. Unfortunately, patients may ex-
perience profound fatigue for weeks to months after
resolution of acute pneumonia34 with a delay in diagnosis
not uncommon. If early diagnosis and the initiation of treat-
ment in a timely fashion alter the natural history of the
disease has yet to be determined.
Radiographic features are nonspeciﬁc and exhibit signiﬁ-
cant variation in appearance during the course of primary
infection. Patients may have a normal and unrevealing chest
X-ray, although classic ﬁndings include segmental or lobar
pneumonia. Pleural effusions can occur in a small proportion
of patients and vary from small and clinically insigniﬁcant
effusions to empyema requiring thorascopic surgery. The
pleural ﬂuid is often exudative with a high percentage of
eosinophils.35 The size of the effusion does not correlate with
risk of dissemination.36,37
Pulmonary coccidioidomycosis often has associated intra-
thoracic lymphadenopathy with hilar and/or mediastinal
nodes enlarged in up to 20% of patients undergoing computed
tomographic (CT) imaging.38 Traditionally, lymphadenopathy
was thought to demonstrate regional spread from the pul-
monary parenchyma to the lymphatic system and represent
early disseminated disease. However, further studies have
disproven this presumed association.39
Severe presentations of primary coccidioidomycosis are
uncommon and are typically observed in patients with
underlying immunological deﬁcits or following a high burden
of exposure resulting in diffuse multilobar pneumonia. Re-
spiratory failure and ARDS may be seen in these groups.40
Miliary disease also has been reported in acute pneumonia
and indicates hematogenous or lymphatic spread. Imaging
ﬁndings show multiple, small, millet-seed nodules through-
out the lung parenchyma that is radiographically indistin-
guishable from tuberculosis.41
It is essential to follow pulmonary inﬁltrates from Cocci-
dioides to resolution with repeat imaging 2 to 3 months after
the initial infection. The initial inﬁltrate may “heal” with a
resultant pulmonary nodule and persist for decades
(►Fig. 4a, b). If an antecedent history of coccidioidomycosis
is not known, or patients are not adequately educated about
the sequelae from their initial infection, these nodules can be
indistinguishable from malignancy and in many cases, unfor-
tunately, undergo surgical resection. Efforts are ongoing in an
attempt to differentiate coccidioidal nodules from nodules
caused byother etiologies.11,41,42Despite the inclusion of skin
testing and serologic testing in these protocols, positive
noninvasive testing with an unclear temporal relation to
radiologic ﬁndings is not typically helpful and certainly
does not rule out the possibility of malignancy.
Complications of Primary Infection
As the acute infection resolves, initial inﬁltrates or nodules
can also undergo excavation resulting in thick- or thin-walled
cavities (►Fig. 5). The cavity may vary over time and can
result in signiﬁcant complications even in immunocompetent
hosts.43 Ruptured cavities near the pleural surface can result
in bronchopleural ﬁstulas or a hydropneumothorax.41 Small
cavitary lesionsmay resolve spontaneously, but in some cases
surgical resection or debridement may be required although
this option is reserved for those with continued symptoms or
complications attributed to coccidioidal cavities.
A small proportion of patients with acute pneumonia will
develop chronic ﬁbrocavitary disease.38 Patients experience
persistent cough and sputum production as well as fevers,
night sweats, and weight loss.41 In most cases, serological
testing will remain positive. Various radiological abnormali-
ties can be present including inﬁltrates involving multiple
lobes and areas of cavitation.43 Additional complications of
cavitary disease include the development of a fungus ball by
either Aspergillus spp. or a bacterial superinfection.41 Occa-
sionally, hyphal forms of Coccidioides spp. have been isolated
from cavitary lesions, suggesting the presence of a coccidioi-
dal fungus ball.44
Extrapulmonary coccidioidomycosis can involve anyorgan
system. Disseminated disease more frequently occurs in
patients with known immunosuppression, severe comorbid-
ities, or those of African American or Filipino ethnicity.
However, approximately 1 to 3% of “immunocompetent”
patients develop extrapulmonary manifestations.43 The
most common organ systems involved include skin, bones,
joints, and lymph nodes. Infection in the bone can occur by
direct inoculation but often is caused by hematogenous
spread. Vertebral osteomyelitis is one of the most
Fig. 3 A rupturing Coccidioides spherule producing hundreds of
endospores.
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difﬁcult-to-manage non-central nervous system (CNS)
complications. It requires systemic antifungal therapy and
may require surgical debridement to control the infection and
provide stabilization of the spine.45
Patients with disseminated disease often have signiﬁcant-
ly elevated complement ﬁxation (CF) titers and management
of these patients has signiﬁcant variability among providers.
Many physicians recommend routine cerebrospinal ﬂuid
(CSF) analysis and/or bone scans in all patients if serum CF
titers are more than 1:16. However, recent work has found
this approach unhelpful and patient symptoms and exam
ﬁndings should instead guide diagnostic testing rather than
an algorithmic approach to patient management.46
Meningitis is the most feared complication of extrapulmo-
nary coccidioidomycosis. Coccidioidal meningitis most fre-
quently develops within the ﬁrst few months after initial
infection, although cases have been observed years after the
Fig. 4 (a) A patient referred for evaluation of a pulmonary nodule. On review, previous chest X-rays documented the resolution of primary
coccidioidal pneumonia with a resultant pulmonary nodule (arrow). (b) The patient also underwent CT scan of the chest for further
characterization of the nodule prior to referral.
Fig. 5 A thick-walled cavity caused by coccidioidomycosis abutting
the pleura.
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primary infection.47 Additionally, treatment of acute cocci-
dioidal infections does not appear to alter the rate of dissem-
ination,48 and after cessation of antifungal therapy following
resolution of acute disease, patients must be followed up for
recurrence or the development of symptoms compatiblewith
extrapulmonary dissemination.
Although meningitis may present with a rapid course, it
more frequently represents chronic meningitis with vague
symptoms and an insidious onset. Patients with a history of
coccidioidal infection and persistent headaches should be
evaluated for possible CNS disease by radiographic imaging
and lumbar puncture. Other less common symptoms include
nausea, vomiting, and vision changes related to increased
intracranial pressure.49 Diagnosis is conﬁrmed by serological
testing for Coccidioides spp. from spinal ﬂuid, as fungal
cultures are frequently negative. Associated ﬁndings within
the CSF include a leukocytosis with lymphocytic predomi-
nance, occasionally eosinophils, and a low level of glucose.
Vasculitis with resulting cerebral infarction occurs in up to
50% of patients with CNS disease in some series. Pathological
examination of tissue from these patients has revealed en-
darteritis obliterans50 and may require adjunctive treatment
with high-dose corticosteroids, although there is no consen-
sus of opinion on this approach to therapy. Hydrocephalus
occurs in 30 to 50% of patients47 and requires urgent neuro-
surgical evaluation and prompt relief of the elevated intra-
cranial pressure when feasible. These sequelae of CNS disease
account for the highest mortality in coccidioidomycosis.50
Diagnosis
A ﬂu-like illness following travel or residence within an
endemic area suggests the diagnosis. Concurrent features
such as the development of a skin rash and/or a peripheral
eosinophilia are additional diagnostic clues suggesting the
illness is coccidioidomycosis rather than bacterial or viral in
origin.
Acute infection can be difﬁcult to diagnose owing to the
nonspeciﬁc and myriad presentations of the disease. It is
common for the diagnosis to be delayed, even within the
endemic region among practitioners familiar with the dis-
ease. As the vast majority of patients fully recover following
acute infection, a signiﬁcant number of patients are never
diagnosed making the exact burden of infection difﬁcult to
estimate.
Isolation of Coccidioides spp. in culture is the most deﬁni-
tivemethod of diagnosis. The organism can be recovered from
biopsied specimens, sputum, and skin lesions, while isolation
from other sites (e.g., CSF, pleural, or joint ﬂuid) is much less
common. Isolation from any location or body ﬂuid is diag-
nostic of proven infection.43 Coccidioides spp. do not require
special media for growth and the organism can be recognized
3 to 5 days after inoculation onto routine media. The mold
form of Coccidioides produces highly infectious arthroconidia
as soon as 72 hours after initial growth. This form represents a
signiﬁcant risk of inhalational exposure to laboratory person-
nel and all specimens should be handled under biosafety level
3 conditions.
Identiﬁcation of the characteristic spherules or endo-
spores on pathologic specimens also conﬁrms the diagnosis.
Spherules are typically 20 to 80 µm in diameter and are best
observed with periodic acid–Schiff or Gomori methenamine
silver stains. The tissue often demonstrates a granulomatous
reaction with ﬁbrosis and caseation in chronic lesions.
Owing to the challenges of demonstrating proven infec-
tion, and the risks inherent with laboratory isolation of the
mold form, noninvasive methods are more frequently em-
ployed. Latex agglutination assays and enzyme-linked im-
munoassays demonstrating serologic positivity are
commercially available but are not speciﬁc.51,52 Testing of
CSF or sera by these methods commonly results in false-
positive ﬁndings, limiting their clinical utility or usefulness in
epidemiologic evaluation.53
Immunodiffusion and CF testing remain the most speciﬁc
method for diagnosis,37 although it is important to recognize
interlaboratory variation. Testing is based on identiﬁcation of
IgM or IgG antibodies to coccidioidal antigens by immunodif-
fusion. In acute infection, nearly half of patients will have
detectable IgM within the ﬁrst week and approximately 90%
by the thirdweek.43,54 Although IgM decreases over time, IgG
becomes detectable within 1 to 3 months of acute infection
and often persists for 6 to 8 months or longer. Quantitative
results from CF testing are helpful in assessing disease
severity, correlating with patient symptoms, and assessing
a therapeutic response.35 Although the CF titer is used as a
surrogate marker for the burden of disease, immunocompe-
tent patients with a low CF titer may have signiﬁcant, albeit
sequestered, infection, such as within the CNS or a joint
space.43
A small percentage of patients do not have a detectable
antibody response. This usually occurs in patients with
signiﬁcant immunosuppression or early in the course of
infection prior to the development of coccidioidal antibodies.
Diagnosis in selected solid-organ transplant recipients can be
particularly difﬁcult due to the decreased sensitivity of
serological testing in this population. This potentially can
be explained by the hindered immune response due to
antirejection medications. Multiple test modalities may be
needed as well as repeated testing over time to detect an
immune response in these patients.55
Antigen detection can be used to assist with diagnosis,
particularly in patients unable to exhibit a robust immuno-
logical response. Prior diagnostic testing of patients with
coccidioidomycosis noted that these patients had false-
positive testing for Histoplasma urinary antigen. Owing to
this, a coccidioidal urinary antigen test was developed
exhibiting a sensitivity of 71% in highly immunocompro-
mised patients.40 It should be noted that the sensitivity
varies greatly in different patient populations and antigen
testing generally has little clinical utility in immunocom-
petent patients. Similarly, serum (1!3)-β-D-glucan (BG),
an antigenic component of the fungal cell wall, has been
evaluated in the diagnosis of coccidioidomycosis, with
disappointing results.56
Owing to the need for rapid and sensitive diagnostic
testing, interest has increased for polymerase chain reaction
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(PCR)-based testing for coccidioidomycosis. Previous studies
have demonstrated excellent sensitivity and speciﬁcity on
isolate material and from sputum in active cases. However,
results from the study of other clinical sites have not been as
promising.57,58 PCR-based testing appears to have a high
negative predictive value, although the sensitivity is overall
similar to fungal cultures. Additional testing on clinical
samples is needed for further evaluation of the utility of
PCR in coccidioidal diagnostics.59
Treatment
There are stark differences in treatment practices between
physicians in the treatment of acute coccidioidal pneumonia.
Many physicians advocate for observation rather than anti-
fungal treatment, as most patients will eventually clear the
infection without long-term sequelae. However, the relative
infrequency of signiﬁcant toxicity with short-term triazole
usehas prompted others to insist on the treatment of virtually
all symptomatic patients with coccidioidomycosis. Treatment
of acute pneumonia theoretically may reduce the duration of
symptoms, although speculation that treatment may reduce
the risk of dissemination appears without merit—a single
observational study has suggested there is unlikely to be a
signiﬁcant impact on dissemination rates in those receiving
and those not receiving antifungal therapy for acute cocci-
dioidal pneumonia.48
Current guidelines recommend treatment of patients
with underlying immunosuppression, signiﬁcant comor-
bidities, those with prolonged infection, and those with CF
titers exceeding 1:32.5,60 Additionally, most clinicians ex-
perienced in the care of coccidioidomycosis have a low
threshold to treat African American or Filipino patients
given the severity of disease that is commonplace in these
ethnicities. Other factors favoring treatment include
weight loss of more than 10%, night sweats for longer
than 3 weeks, inﬁltrates of more than one-half of one
lung or portions of both lungs, and prominent or persistent
hilar adenopathy.60
Prior to the availability of azoles, amphotericin B was the
only available agent with reliable antifungal activity, sub-
jecting patients to prolonged intravenous therapy and sig-
niﬁcant risks for the toxicity inherent with polyenes. The
development of triazoles thus revolutionized the care of
coccidioidomycosis. Fluconazole has excellent bioavailabili-
ty, is available as an oral formulation, has few drug–drug
interactions, and is well tolerated even at high doses.41 It has
been demonstrated effective for the treatment of coccidioi-
domycosis and is the preferred agent for pulmonary and CNS
disease.61
The duration of therapy varies on the site and severity of
disease. Typically, 3 to 6 months is preferred for primary
pulmonary disease and many recommend clinical follow-up
for a year or longer after initial infection.60 In contrast,
chronic pulmonary disease often requires life-long therapy
to preserve lung function and avoid continued lung destruc-
tion. Although there are no studies evaluating the recom-
mended interval of serological testing, typically testing is
performed every 2 to 4months depending on disease severity
and the clinical response to treatment.43
The efﬁcacy of itraconazole for extrapulmonary disease
and chronic infection has been well established62 and it is
accepted as the preferred therapy for skeletal disease based
on a blinded comparative study with ﬂuconazole.61 Itraco-
nazole is available in both solution and capsular form. The
capsule and oral solution are not bioequivalent and are thus
not interchangeable. The solution is preferred due to im-
proved bioavailability. Patients should be counseled to take
itraconazole solution on an empty stomach, as it is best
absorbed in the fasting state. In contrast, the capsules require
a high-fat meal with an acidic beverage to maximize absorp-
tion.41 Itraconazole serum levels should be evaluated to
ensure clinically relevant concentrations are observed, and
in patients with levels less than 0.5 µg/mL, adjunctive meas-
ures to enhance absorption should be reviewed at each visit.
The role of the newer azoles, voriconazole, posaconazole,
and isavuconazole, in the care of coccidioidomycosis has yet
to be deﬁned primarily due to cost concerns when these
agents are used as primary therapy. The extended-spectrum
triazoles have excellent in vitro activity against Coccidioides
spp. and both voriconazole and posaconazole have proven
useful in patients intolerant of, or refractory to, other anti-
fungal agents.63,64 Voriconazole is an attractive choice for
meningeal disease due to its penetration and detectable levels
within the CSF.41 However, treatment is limited by toxicity
with long-term use,65 frequent drug–drug interactions, and
the need for therapeutic drugmonitoring.66 Posaconazole has
also proven efﬁcacious in pulmonary and disseminated dis-
ease.64 Although therapy is well tolerated with few adverse
events, there are no studies to date to suggest it is more
effective than ﬂuconazole or itraconazole in humans.67 Isa-
vuconazole is the newest member of the triazole class and
experience in the treatment of coccidioidomycosis with this
agent is limited currently.
Pregnancy represents a unique challenge in the treatment
of coccidioidomycosis given the teratogenicity of azoles in the
ﬁrst trimester.68 The relative immunosuppression of preg-
nancy and elevation in host estrogen levels promoting in vivo
fungal growth have prompted the use of amphotericin B
formulations in this population with lipid formulations gen-
erally preferred. Some experts recommend azoles during the
second and third trimester when the risk of teratogenicity is
lower to avoid prolonged intravenous amphotericin B
administration.
Meningeal disease can be particularly challenging to man-
age. Most physicians recommend treatment of mild to mod-
erate meningitis with ﬂuconazole due to its excellent
bioavailability and penetration into the CSF. The typical
ﬂuconazole dose is 400 mg/day but doses of 800 to 2,000
mg/day are commonly used for meningeal disease.47 Anti-
fungal therapy should be continued indeﬁnitely given the
high relapse rates when therapy is discontinued.69,70 Occa-
sionally, physicians still are forced to use intrathecal ampho-
tericin; however, this approach is reserved for patients with
severe disease or cases in which azoles fail given the toxicity
of intrathecal therapy.69,71
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There is no consensus of opinion regarding optimal therapy
for patients with refractory infection requiring salvage thera-
py. Antifungal resistance has not been proven to play a
signiﬁcant role in patients failing traditional therapy and
reports of Coccidioides isolates with elevated ﬂuconazole
minimum inhibitory concentrations (MICs) are rare.72 Al-
though susceptibility testing is available in reference laborato-
ries, its usefulness in guiding treatment decisions has not been
studied. In addition, MIC determination is performed in the
mold phase, while the spherule/endospore (S/E) phase MICs
are theoretically more applicable to patient care.5 Lipid am-
photericin B formulations are preferred for moderate to severe
disease and refractory cases to regain control of the infection.
Alternatively, extended spectrum triazoles have been used in
cases of more limited disease, although therapeutic drug
monitoring is recommended when using these agents.5
Echinocandins have minimal inherent activity against
Coccidioides spp. and should not be used as monotherapy in
the treatment of coccidioidomycosis. They have demonstrat-
ed potential efﬁcacy when used in combination with other
antifungal agents in murine models of infection.73 Recently,
salvage studies have also demonstrated their potential
utility.74
New Directions
Studies of patients with chronic and disseminated disease
have noted decreased production of interferon-gamma
(IFN-γ)75,76 and defects within the interleukin-12/IFN-γ
pathway.77,78Owing to theseﬁndings, there has been interest
in the administration of IFN-γ to enhance thehost response to
coccidioidomycosis. Prospective trials have not been per-
formed, but successful adjunctive use in salvage therapy
has been reported,79 although long-term use is limited by
both patient tolerability and expense.
The antifungal drug nikkomycin Z has been long awaited
and may represent a breakthrough in the treatment of
coccidioidomycosis. It has demonstrated excellent in vitro
activity against Coccidioides spp., has a unique mechanism of
action, and studies have shown efﬁcacy in naturally infected
dogs and experimentally infected mice.80,81 Recent work has
focused on developing a dosing framework in preparation for
phase 2 and 3 clinical trials.82
It has been recognized since the 1940s that individuals
who recovered from coccidioidomycosis have durable immu-
nity to reinfection, with the exception of severely immuno-
suppressed patients.83 These observations suggest a role for a
vaccine to be developed protecting recipients from symptom-
atic disease. Despite extensive work on development, no
commercially available vaccine exists to date.
Conclusion
Coccidioidomycosis continues to represent a signiﬁcant med-
ical problem within endemic regions. Substantial questions
remain regarding the ecology, epidemiology, immune re-
sponse, and optimal treatment of this infection.11 The
National Institutes of Health and Centers for Disease Control
and Prevention have recently redoubled efforts to answer
many of these questions and signiﬁcant advances have been
made in a short time. A large-scale double-blind placebo
controlled trial has also beenproposed in an attempt to clarify
the role of antifungals in the treatment of primary pulmonary
coccidioidomycosis. The next decade will undoubtedly see
the answers to many of the oldest questions in this ﬁeld, and
our patients care improved as a result.
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